|
|
Ukrain
(NSC-631570) in experimental and clinical studies: a review
Jagiello-Wojtowicz
E, Kleinrok Z, Urbanska EM
Department
of Pharmacology and Toxicology, Medical University School, Lublin, Poland
The need
to find a safe and highly effective cure for neoplastic disease remains a major
challenge for modern pharmacology. This paper reviews the available literature
on Ukrain (NSC631570), a novel semisynthetic drug obtained from Chelidonium
majus L. alkaloids.
Ukrain has been demonstrated to possess antineoplastic and immunomodulatory
properties.
Inhibition of the growth of cancer cell lines in vitro, tumor mass reductions in
vivo, and partial and complete remissions in oncological patients, occur as a
result of Ukrain application.
The drug may interfere directly with the metabolism of cancer cells and it also
improves the functioning of the host immune system.
Diminished synthesis of DNA, RNA and proteins, the inhibition of cellular oxygen
consumption, and the induction of programmed cell death in malignant cells have
been described following Ukrain administration.
The drug can also modify the immunological response via an increase in the
number of total T-cells and a normalization of the T-helper/T-suppressor
lymphocyte ratio.
Ukrain therapy produces neither toxic consequences nor allergic reactions
towards the drug.
Several case reports and clinical trial data indicate that Ukrain may ameliorate
effectively the progress of neoplastic disease and/or induce a total cure.
PMID:
10190077 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10190077&dopt=Abstract
|
